Longevity in Anti-VEGF Inhibitors Utilized in AMD/DME

home / insights / longevity-in-anti-vegf-inhibitors-utilized-in-amd-dme

Retina specialists discuss 2-year data updates in the TENAYA, LUCERNE, YOSEMITE, and RHINE trials for wet macular degeneration (wet AMD) and diabetic macular edema (DME).

EP. 1: Impact of AMD and DME on Quality of Life

David A. Eichenbaum, MD;Caroline Baumal, MD

August 30th 2022

David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, discuss how AMD and DME impact a patient’s quality of life.

EP. 2: AMD and DME: Factors Affecting Treatment Selection and the Importance of Shared Decision-Making

David A. Eichenbaum, MD;Caroline Baumal, MD

August 30th 2022

Retina specialists discuss which factors impact treatment selection and how to incorporate shared decision-making into treatment selection when treating patients with AMD and DME.

EP. 3: Implications of Treat-and-Extend With Faricimab in AMD

David A. Eichenbaum, MD;Caroline Baumal, MD

August 30th 2022

Drs David A. Eichenbaum and Caroline Baumal discuss implications of the treat-and-extend approach with faricimab in patients with wet AMD.

EP. 4: MOA of Faricimab and 2-Year Data Review

David A. Eichenbaum, MD;Caroline Baumal, MD

August 30th 2022

David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, review the dual mechanism of action of faricimab as well as the 2-year update in the TENAYA, LUCERNE, YOSEMITE, and RHINE trials.

EP. 5: Incorporating Faricimab in Clinical Practice

David A. Eichenbaum, MD;Caroline Baumal, MD

August 30th 2022

Retina specialists discuss how to incorporate faricimab into clinical practice and discuss implacations of the TRUCKEE study.

EP. 6: Unmet Needs in AMD and DME

David A. Eichenbaum, MD;Caroline Baumal, MD

August 30th 2022

Drs David A. Eichenbaum and Caroline Baumal discuss unmet needs in treating AMD and DME.

EP. 7: Take-Home Points for the Treatment of AMD and DME

David A. Eichenbaum, MD;Caroline Baumal, MD

August 30th 2022

David A. Eichenbaum, MD, FASRS and Caroline Baumal, MD provide take-home messages to providers treating AMD and DME.